Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	6.94B -15.7%
Revenue (ttm)	1.19B +3.3%
Net Income	355.94M +26.6%
EPS	0.89 +25.5%
Shares Out	385.74M
PE Ratio	20.21
Forward PE	18.74
Dividend	0.45 (2.26%)
Ex-Dividend Date	May 18, 2026

Volume	23,018,005
Open	18.44
Previous Close	19.90
Day's Range	17.60 - 21.41
52-Week Range	17.66 - 26.15
Beta	0.36
Analysts	Strong Buy
Price Target	29.08 (+61.65%)
Earnings Date	Jul 28, 2026

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,175
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2025, Amoy Diagnostics's revenue was 1.20 billion, an increase of 8.01% compared to the previous year's 1.11 billion. Earnings were 361.26 million, an increase of 41.74%.

Analyst Summary

According to 6 analysts, the average rating for 300685 stock is "Strong Buy." The 12-month stock price target is ¥29.08, which is an increase of 61.65% from the latest price.

Price Target

¥29.08

(61.65% upside)

Analyst Consensus: Strong Buy